Anhui Huaheng Biotechnology Co. Ltd. A Total Assets
Anhui Huaheng Biotechnology Co. Ltd. A total assets. Based on the latest financial reports, Anhui Huaheng Biotechnology Co. Ltd. A (688639) holds total assets worth CN¥6.03 Billion CNY (≈ $881.78 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Anhui Huaheng Biotechnology Co. Ltd. A worth for the company's overall valuation and market capitalisation.
Total Assets of Anhui Huaheng Biotechnology Co. Ltd. A (2012–2025)
Total assets of Anhui Huaheng Biotechnology Co. Ltd. A from 2012 to 2025. This chart illustrates how Anhui Huaheng Biotechnology Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. See today's stock price for Anhui Huaheng Biotechnology Co. Ltd. A for real-time trading data and today's change.
Anhui Huaheng Biotechnology Co. Ltd. A - Asset Composition Analysis
Anhui Huaheng Biotechnology Co. Ltd. A Total Assets Breakdown (December 2025)
Anhui Huaheng Biotechnology Co. Ltd. A total assets breakdown as of December 2025. Anhui Huaheng Biotechnology Co. Ltd. A's total assets of CN¥6.03 Billion consist of 25.4% current assets and 74.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 4.9% |
| Accounts Receivable | CN¥587.63 Million | 10.2% |
| Inventory | CN¥532.13 Million | 9.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥150.04 Million | 2.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Anhui Huaheng Biotechnology Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Anhui Huaheng Biotechnology Co. Ltd. A's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Anhui Huaheng Biotechnology Co. Ltd. A's current assets represent 25.4% of total assets in 2025, a decrease from 65.6% in 2012.
- Cash Position: Cash and equivalents constituted 4.9% of total assets in 2025, down from 22.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 3.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 10.2% of total assets.
Anhui Huaheng Biotechnology Co. Ltd. A Competitors by Total Assets
Key competitors of Anhui Huaheng Biotechnology Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $752.18 Million |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
Anhui Huaheng Biotechnology Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.21 | 1.03 | 4.83 |
| Quick Ratio | 0.77 | 0.69 | 4.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥304.43 Million | CN¥40.62 Million | CN¥668.20 Million |
Anhui Huaheng Biotechnology Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Anhui Huaheng Biotechnology Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.55 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 15.7% |
| Total Assets | CN¥5.77 Billion |
| Market Capitalization | $618.54 Million USD |
Valuation Analysis
Below Book Valuation: The market values Anhui Huaheng Biotechnology Co. Ltd. A's assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Anhui Huaheng Biotechnology Co. Ltd. A's assets grew by 15.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Anhui Huaheng Biotechnology Co. Ltd. A (2012–2025)
The table below shows the annual total assets of Anhui Huaheng Biotechnology Co. Ltd. A from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥5.77 Billion ≈ $845.02 Million |
+15.74% |
| 2024-12-31 | CN¥4.99 Billion ≈ $730.11 Million |
+25.67% |
| 2023-12-31 | CN¥3.97 Billion ≈ $580.97 Million |
+95.86% |
| 2022-12-31 | CN¥2.03 Billion ≈ $296.63 Million |
+37.51% |
| 2021-12-31 | CN¥1.47 Billion ≈ $215.71 Million |
+98.43% |
| 2020-12-31 | CN¥742.89 Million ≈ $108.71 Million |
+32.40% |
| 2019-12-31 | CN¥561.09 Million ≈ $82.10 Million |
+3.69% |
| 2018-12-31 | CN¥541.13 Million ≈ $79.18 Million |
+31.32% |
| 2017-12-31 | CN¥412.06 Million ≈ $60.30 Million |
+6.74% |
| 2016-12-31 | CN¥386.04 Million ≈ $56.49 Million |
+33.49% |
| 2015-12-31 | CN¥289.20 Million ≈ $42.32 Million |
+52.28% |
| 2014-12-31 | CN¥189.91 Million ≈ $27.79 Million |
+2.66% |
| 2013-12-31 | CN¥184.98 Million ≈ $27.07 Million |
+46.92% |
| 2012-12-31 | CN¥125.90 Million ≈ $18.42 Million |
-- |
About Anhui Huaheng Biotechnology Co. Ltd. A
Anhui Huaheng Biotechnology Co., Ltd. engages in the research and development, production, and sale of bio-based products through bio-manufacturing in China and internationally. The company offers amino acid products, including the alanine series, L-valine, isoleucine, tryptophan, and arginine; vitamin products, such as D-calcium pantothenate, D-panthenol, and inositol; bio-based new material mon… Read more